Abstract: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.

Abstract: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.

Abstract: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.

Abstract: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.

Abstract: The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin.

Abstract: The present invention provides a rapid and efficient method for the preparation and isolation of biologically active polysaccharides from Aloe. The present invention includes the activated mixture of polysaccharides (referred to herein as “Immuno-10”), produced by the methods of the invention. The invention also includes the use of the polysaccharides as immunostimulating, immunomodulating and wound healing agents. The resulting immunomodulatory complex has a higher activity and is more stable than bulk carbohydrates isolated using prior art alcohol precipitation schemes.

Abstract: The present invention discloses aqueous compositions comprising liposomes of phospholipids, and at least one competitive inhibitor of an enzyme for the synthesis of melanin, in combination with at least one non-competitive inhibitor of an enzyme for the synthesis of melanin. The invention also includes the use of the compositions of this invention for the de-pigmentation of skin.

Abstract: The present invention discloses a method for the synthesis of derivatives of aloesin, alkylated at the C-7 hydroxyl group. The present invention includes the modified aloesins produced by the method of this invention and the use of these compounds as skin whitening agents.

Abstract: The present invention discloses a two-step method for the preparation of 8-C-.beta.-D-?2'-O-(E)-cinnamoyl!glycopyranosyl-2-?2-hydroxy!propyl-7-meth oxy-5-methylchromone (the "540 compound) from the readily available 5-methylchromone, Aloesin.

Abstract: The present invention provides a process for purifying the cinnamoyl-C-glycoside, 8-C-.beta.-D-?2-O-(E)-cinnamoyl!glycopyranosyl-2- ?(R)-2-hydroxy!propyl-7-methoxy-5-methyl-chromone, referred to herein as the "540 compound." In one embodiment of the present invention the 540 compound is purified by extraction from a decolorizing agent with an organic solvent. The extracted product can be further purified by high pressure liquid chromatography. In a second embodiment crude 540 compound, which has not been treated with a decolorizing agent, is purified by passage over neutral alumina or sephadex.

Abstract: The present invention provides a process for purifying the cinnamoyl-C-glycoside, 8-C-&bgr;-D-[2-O-(E)-cinnamoyl]glycopyranosyl-2- [(R)-2-hydroxy]propyl-7-methoxy-5-methyl-chromone. 8-C-&bgr;-D-[2′-O- (E)-cinnamoyl]glycopyranosyl-2-[(S) -2-hydroxy]propyl-7-methoxy-5-methylchromone, referred to herein as the “540 compound.” In one embodiment of the present invention the 540 compound is purified by extraction from a decolorizing agent with an organic solvent. The extracted product can be purified by high pressure liquid chromatography. In a second embodiment crude 540 compound, which has not been treated with a decolorizing agent, is purified by passage over neutral alumina or sephadex.